Otsuka's VOYXACT Shows Long-Term Kidney Function Improvement in IgAN Phase 3 Trial
Event summary
- VOYXACT demonstrated statistically significant stabilization of kidney function over two years in the Phase 3 VISIONARY trial.
- The drug met KDIGO 2025 guidelines for reducing kidney function decline to near physiological levels (<1 mL/min/1.73 m² per year).
- Otsuka plans to submit these results to support marketing applications, including an sBLA for traditional FDA approval.
- VOYXACT was well tolerated with a favorable safety profile consistent with prior interim results.
The big picture
Otsuka's positive Phase 3 results for VOYXACT mark a significant advancement in treating IgA nephropathy, a progressive kidney disease with limited therapeutic options. The data support selective APRIL inhibition as a precise, disease-modifying approach, distinguishing VOYXACT from broader B-cell depletion therapies. This positions Otsuka to potentially dominate the IgAN treatment landscape if regulatory approvals proceed smoothly.
What we're watching
- Regulatory Approval
- Whether the FDA will grant traditional approval based on the two-year eGFR data, following the accelerated approval in November 2025.
- Market Positioning
- How Otsuka positions VOYXACT against existing and emerging therapies for IgAN, leveraging its selective APRIL inhibition mechanism.
- Long-Term Efficacy
- The pace at which additional data from the open-label extension study (NCT05248659) will reinforce VOYXACT’s disease-modifying potential.
Related topics